Journal of Clinical Oncology

The Journal of Clinical Oncology is the flagship peer-reviewed journal of the American Society of Clinical Oncology (ASCO), published on behalf of ASCO by Lippincott Williams & Wilkins (Wolters Kluwer) and founded in 1983, disseminating significant clinical cancer research and practice-changing information on the diagnosis and treatment of cancer, with a 2025 Journal Impact Factor of 44.7《临床肿瘤学杂志》是美国临床肿瘤学会（American Society of Clinical Oncology，ASCO）的旗舰同行评审期刊，由（Lippincott Williams & Wilkins）即（Wolters Kluwer）代表（ASCO）出版、1983 年创办，刊载重要的临床癌症研究与改变实践的癌症诊疗信息，2025 年影响因子为 44.7。

Scope

• It serves its readers as the single most credible and authoritative resource for disseminating significant clinical oncology research该刊作为传播重要临床肿瘤学研究成果的权威资源，服务于其读者。
• In print and in electronic format it strives to publish the highest quality articles dedicated to clinical research该刊以印刷版与电子版形式，致力于刊载专注于临床研究的最高质量文章。
• Original Reports remain the focus, enhanced by appropriately selected Editorials, Commentaries and Reviews that relate to the care of patients with cancer原创论文是其核心，并以经甄选的社论、评论与综述加以充实，均与癌症患者的照护相关。
• It publishes practice-changing clinical cancer research and is the authoritative source for current information on the diagnosis and treatment of patients with cancer该刊刊载改变临床实践的癌症研究，是癌症患者诊断与治疗最新信息的权威来源。
• It publishes ASCO clinical practice guidelines, Special Articles, Comments and Controversies, and Biology of Neoplasia该刊刊载（ASCO）临床实践指南、特别文章、评论与争鸣（Comments and Controversies），以及肿瘤生物学（Biology of Neoplasia）类文章。
• Article types include Original Reports, Review Articles, Comments and Controversies, Biology of Neoplasia, Art of Oncology, Editorials and Correspondence文章类型包括原创论文、综述文章、评论与争鸣、肿瘤生物学、肿瘤人文（Art of Oncology）、社论与读者来信。
• Manuscripts on cancer epidemiology with population-based or well-defined study populations are a priority for the journal基于人群或研究人群明确的癌症流行病学稿件是该刊的优先方向。
• It is published three times per month in print and continuously online该刊每月出版三期，并持续在线更新。

History

• The journal was founded by ASCO in 1983, and its first issue appeared as Volume 1, Number 1, in January 1983, with Joseph R. Bertino as the first Editor-in-Chief该刊由（ASCO）于 1983 年创办，首期于 1983 年 1 月以第 1 卷第 1 期出版，Joseph R. Bertino 出任首任主编。^[1]
• In the inaugural issue Bertino wrote that the aim of the journal was to be a focus for communication for research pertaining to the clinical disciplines of oncology, appealing to the broadest possible interdisciplinary readership在创刊号中 Bertino 写道，该刊旨在成为肿瘤临床学科研究的交流中心，面向尽可能广泛的跨学科读者。
• Its Editors-in-Chief have been Joseph R. Bertino (1983-1988), George P. Canellos (1988-2001), Daniel G. Haller (2001-2011), Stephen A. Cannistra (2011-2021) and Jonathan W. Friedberg (2021 to present)历任主编依次为 Joseph R. Bertino（1983-1988）、George P. Canellos（1988-2001）、Daniel G. Haller（2001-2011）、Stephen A. Cannistra（2011-2021）与 Jonathan W. Friedberg（2021 年至今）。^[2]
• It marked its 40th anniversary with retrospective content celebrating four decades of advances in cancer care该刊以回顾性内容纪念创刊四十周年，庆祝癌症照护四十年的进展。
• It is published on behalf of ASCO by Lippincott Williams & Wilkins, part of Wolters Kluwer, and its journal family grew to include JCO Oncology Practice, JCO Global Oncology, JCO Precision Oncology, JCO Clinical Cancer Informatics and JCO Oncology Advances该刊由（Wolters Kluwer）旗下的（Lippincott Williams & Wilkins）代表（ASCO）出版，其期刊家族先后扩展出（JCO Oncology Practice）、（JCO Global Oncology）、（JCO Precision Oncology）、（JCO Clinical Cancer Informatics）与（JCO Oncology Advances）。
• Its 2025 Journal Impact Factor is 44.7, placing it in the first quartile of the oncology category of the Journal Citation Reports该刊 2025 年影响因子为 44.7，位列（Journal Citation Reports）肿瘤学类别的第一四分位。

Editors

• The Editor-in-Chief is Jonathan W. Friedberg, MD, MMSc, of the University of Rochester, USA, who has led the journal since June 2021现任主编为 Jonathan W. Friedberg，医学博士，来自（University of Rochester），自 2021 年 6 月起执掌该刊。
• The Senior Deputy Editor is Kathy D. Miller of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and the Deputy Editor is Alexia Iasonos of Memorial Sloan Kettering Cancer Center高级副编辑为 Kathy D. Miller，来自（Indiana University Melvin and Bren Simon Comprehensive Cancer Center）；副编辑为 Alexia Iasonos，来自（Memorial Sloan Kettering Cancer Center）。
• Associate Editors are international, including Smita Bhatia, Charles Craddock, Chiara Cremolini, Grant McArthur, Andrea Necchi, Eileen M. O'Reilly, Mikkael A. Sekeres, Thomas E. Stinchcombe and Camilla Zimmermann, spanning the USA, United Kingdom, Italy, Australia and Canada副编辑具有国际化特征，包括 Smita Bhatia、Charles Craddock、Chiara Cremolini、Grant McArthur、Andrea Necchi、Eileen M. O'Reilly、Mikkael A. Sekeres、Thomas E. Stinchcombe 与 Camilla Zimmermann，遍及美国、英国、意大利、澳大利亚与加拿大。
• The journal runs consultant editors for themed sections and regional editions, including the JCO Chinese Edition led by Shun Lu of Shanghai Jiao Tong University and the JCO Portuguese Edition led by Franklin Fernandes Pimentel in Brazil该刊设有专题板块与地区版的责任编辑，包括由（Shanghai Jiao Tong University）的 Shun Lu 主持的（JCO Chinese Edition），以及由巴西的 Franklin Fernandes Pimentel 主持的（JCO Portuguese Edition）。
• Manuscripts are peer reviewed, and the journal adheres to the ICMJE authorship criteria and requires editors to disclose financial interests through published conflict-of-interest disclosures稿件经同行评审，该刊遵循（ICMJE）作者标准，并要求编辑通过公开的利益冲突声明披露经济利益关系。
• Thomas E. Stinchcombe of Duke Cancer Institute has been named the next Editor-in-Chief, with his term beginning on January 1, 2027Duke Cancer Institute 的 Thomas E. Stinchcombe 已被任命为下一任主编，任期自 2027 年 1 月 1 日起。